The TyG index takes into account the effects of the two key components of metabolic syndrome, namely, fasting glucose and triglyceride, at the same time, which are overproduced by the fatty liver, and due to the advantages of being non-insulin-based, more feasible and less costly than HOMA-IR, it has become an ideal marker of IR for routine clinical applications. This evidence concerns the gene INS and metabolic syndrome.